Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
BrightGene tops Novo drug in diabetes ahead of Zepbound showdown
BrightGene beat semaglutide on a blood sugar endpoint, giving momentum as it barrels toward a readout from a head-to-head trial against tirzepatide.
Nick Paul Taylor
Jun 23, 2025 2:30pm
Biolinq raises $100M to carry glucose sensor patch to the FDA
Apr 22, 2025 12:00pm
Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3
Apr 17, 2025 6:45am
Dexcom survey shows providers opt for tech over drugs in Type 2
Mar 19, 2025 12:20pm
FDA clears Tandem Diabetes insulin-dosing algorithm in Type 2
Feb 25, 2025 2:01pm
Fractyl pivots T2D therapy to obesity & GLP-1s, lays off staff
Jan 31, 2025 11:45am
